Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

158 results about "Substitution therapy" patented technology

Substitution therapy. Substitution therapy is a term used to describe a harm reduction treatment for opioid use disorders where safer versions of the drug substitute for the unsafe, illegal forms. The most common types of substitution therapy are methadone and buprenorphine.

Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders

The present disclosure is directed to methods of treating a steatosis-associated disorder and methods of treating a cytoplasmic glycogen storage disorder, including glycogen storage disease I, glycogen storage disease III, glycogen storage disease IV, and / or conditions associated with a PRKAG2 mutation, by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage. Methods of treating a cytoplasmic glycogen storage disorder by administering a lysosomal enzyme and a second therapeutic agent are also described. Other embodiments are directed to methods of treating a cytoplasmic glycogen storage disorder by administering a therapeutic agent as an adjunctive therapy to lysosomal enzyme replacement therapy.
Owner:DUKE UNIV

Application of mitochondrial acid 5 in preparation of medicine for treating reproductive organ injury caused by diabetes mellitus

The invention provides application of mitochondrial acid 5 in preparation of a medicine for treating reproductive organ injury caused by diabetes mellitus, and relates to the technical field of biological medicine. Experiments prove that as an artificially synthesized indole-3-acetic acid derivative, MA-5 provides a brand new treatment thought for testis injury caused by diabetes mellitus, not only is beneficial to improvement of reproductive function, but also possibly provides a new strategy for overall treatment of diabetes mellitus. Besides, as a natural plant hormone, MA-5 has relatively high safety and acceptability, and possibly becomes a new alternative therapy with a clinical application prospect. Although the long-term administration of the MA-5 does not significantly influence the blood glucose level, the alleviation effect of the MA-5 on testis injury shows that the MA-5 as a treatment means for long-term use can continuously improve reproductive dysfunction caused by diabetes, and has potential clinical advantages.
Owner:HUBEI UNIV OF SCI & TECH

Pharmaceutical preparation of carbohydrates for therapeutic use

InactiveUS20250186345A1Organic active ingredientsLiposomal deliveryGolgi componentNanocarriers
The disclosure provides methods for preparation of carbohydrate replacement therapies (CRT) that include nanocarriers of carbohydrates and glycolipids for pharmaceutical delivery to cell interior, endoplasmic reticulum, and Golgi for treating CDG type I and CDG type II diseases as well as other metabolic disorders.
Owner:GLYCOMINE INC

Gene replacement therapy for ALPK3 cardiomyopathy

PCT designated stage expiredWO2025010312A1Peptide/protein ingredientsTransferasesMedicineGene replacement therapy
The present disclosure relates, in part, to gene replacement to treat cardiomyopathy. In embodiments, the invention provides compositions and methods of use to treat ALPK3 cardiomyopathy. In embodiments, invention provides a composition comprising a nucleic acid encoding all or a portion of an ALPK3 protein.
Owner:RGT UNIV OF CALIFORNIA

Dose escalation enzyme replacement therapy for acid sphingomyelinase deficiency

To provide methods of treating a human subject having non-neurological manifestations of acid sphingomyelinase deficiency (ASMD), and in certain embodiments, NPD subtype B.SOLUTION: A method for treating a human subject having an acid sphingomyelinase deficiency comprises: (a) a regimen for debulking an accumulated sphingomyelin substrate in the human subject including (i) administering an initial low non-toxic dose of an acid sphingomyelinase (ASM) to the human subject, and (ii) administering successively higher doses of ASM to the human subject and monitoring the subject for one or more adverse side effects after each successive dose as indicated by elevated bilirubin or a related adverse event; and (b) a maintenance regimen comprising administering a dose equal to or less than the highest dose tolerated by the subject as a maintenance dose for the subject.SELECTED DRAWING: None
Owner:MT SINAI SCHOOL OF MEDICINE +1

Oral testosterone therapy

Disclosed are methods and compositions for testosterone replacement therapy, especially for use in administration to hypogonadal males. The methods and compositions employ an untitrated dose dosing regimen that does not require titration or dose adjustments and that can provide a therapeutically effective amount of a testosterone ester, such as a non-undecanoate testosterone ester, while avoiding unacceptably high testosterone levels.
Owner:LIPOCINE INC

Testosterone replacement therapy in combination with neuromuscular stimulation

Provided is a method for treating musculoskeletal atrophy in patients suffering from a neurological or neuromuscular disease or disorder by combining testosterone replacement therapy with neuromuscular electrical stimulation of multiple muscle groups and, optionally, physical activity.
Owner:KESSLER FOUND +1

Men1 mutations and uses thereof

Disclosed are mutations in the MEN1 gene of cancer cells that affect sensitivity of the cells to menin-inhibitory therapeutics. Also disclosed are diagnostic tests to detect the mutations. Diagnostic testing of cancer cells from a patient undergoing therapy with menin inhibitors can indicate that the therapy should be changed or stopped. Diagnostic of cells from a patient prior to treatment with a menin inhibitors can indicate an alternative therapy should be used.
Owner:DANA FARBER CANCER INSTITUTE INC +3

Variants of coagulation factor viii and uses thereof

Variants of coagulation factor VIII (FVIII) and expression cassettes encoding the FVIII variants thereof are described. A variant FVIII includes a glycoepitope of the FVIII protein including an N2118Q mutation. The N2118Q mutation can be combined with other mutations including a BDD-FVIII, N6, V3, RH, furin-cleavage site deletion. X10, K12, and / or F309S mutation to form additional FVIII variants. The FVIII variants with the N2118Q mutation and expression cassettes thereof can result in reduced immunogenicity of the resulting protein. When combined with other FVIII mutations, higher gene expression, increased secretion, increased stability, and higher FVIII functional activity can be achieved by the expressed FVIII variants. The variant FVIII and expression cassettes described here can be useful in protein replacement therapy and / or gene therapy for the treatment of hemophilia A.
Owner:SEATTLE CHILDRENS HOSPITAL (DBA SEATTLE CHILDRENS RES INST)

Methods of treating male hypogonadism with hormone-producing organoids

A method of treating male hypogonadism in a subject in need thereof includes administering to the subject testicular organoids generated from isolated male progenitor cells. The method can be used to slow or halt the progression of age-related diseases, and increase healthspan and longevity, in hypogonadal males. The method can be used with subjects that have not or are not receiving testosterone replacement therapy. The method does not require that the subject is pre-treated with CG. The testicular organoid includes cells expressing GFRA1, VEGF, VEGFR2, PDGF-Rα, Cyp11A1, 3β-HSD, 17β-HSD, LHCGR, α-SMA, CD11b, MHC CII, CD64, CD95, Sox9, AR, inhibin β-B, and FSHR.
Owner:ATWOOD CRAIG S +1

Use of semaglutide for the preparation of a medicament for the treatment or delay of ovarian aging

The application relates to application of semaglutide in preparation of a medicine for treating or delaying ovarian aging, and through a natural aging mouse model, a cell aging model and transcriptome analysis, it is first proved that semaglutide can significantly increase the number of follicles and reduce the level of aging markers, and from a molecular level, it is revealed that the mechanism of realizing multi-target point delay of ovarian aging is that semaglutide realizes multi-target point delay of ovarian aging through regulating an adipocyte cytokine signal pathway, inhibiting excessive cell division and regulating an NF-kappa B signal pathway. As a marketed drug, semaglutide has clear safety, a long half-life and high patient compliance, and has a significant clinical conversion prospect. The application breaks through the limitation that existing hormone replacement therapy and assisted reproductive technology can only treat symptoms or solve the problem of fertility, provides a first drug intervention strategy which can fundamentally delay the process of follicle depletion, and fills the blank in the field of ovarian aging treatment.
Owner:NANTONG UNIV

Composite probiotic preparation for improving sensitivity of low-dose nicotine and reducing usage amount of nicotine

PendingCN122081100AIncreased sensitivityCPP score decreasesMilk preparationFungiNicotine replacementsBiochemistry
The invention discloses a composite probiotic preparation capable of improving sensitivity of low-dose nicotine and reducing usage amount of nicotine, and belongs to the crossing field of microbial technology and biological medicine. The compound probiotic preparation only improves the sensitivity of mice to low-concentration nicotine, does not improve the preference of the mice to the existing preference concentration, prevents aggravated smoking addiction, enables individuals to reach the satisfaction of smoking at ordinary times under the condition of low dosage of nicotine, and has the advantages of being simple in preparation process, low in cost and the like. The formulations may be used in combination with products in nicotine replacement therapy or alone. The compound probiotic preparation disclosed by the invention can be used for preparing functional foods, health-care products and medicines capable of improving the sensitivity of the low-concentration nicotine, and has a very wide application prospect.
Owner:JIANGNAN UNIV

Pharmaceutical compositions of testosterone

Stable pharmaceutical compositions are provided, comprising a pharmaceutically effective amount of testosterone or a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable oil vehicle, and a stabilizing amount of benzyl alcohol, for example, about 1% to 3% weight / volume of benzyl alcohol. The present invention also provides a process for stabilizing testosterone-containing pharmaceutical compositions by ageing them at a temperature of about 20° C. to about 60° C. for at least 48 hours, e.g., prior to secondary packing and labeling. These compositions were stable over the shelf life of the product, without exhibiting crystal formation, even upon storing at temperatures of about 2° C. to about 8° C. Other aspects of the invention relate to methods for making such pharmaceutical compositions and methods of using such pharmaceutical compositions for hormone replacement therapy, e.g., in a male patient having a condition associated with symptoms of deficiency or absence of endogenous testosterone.
Owner:AZURITY PHARMA INC

Uses

The disclosure provides methods, treatments and materials for treating diseases or disorders associated with the dopamine D1 receptor intracellular pathway. In particular, the present disclosure provides for methods of treating such diseases and disorders in combination with a dopamine replacement therapy.
Owner:INTRA CELLULAR THERAPIES INC

Methods and compositions for treating 4-hydroxyphenylpyruvate dioxygenase-like (HPDL)-related diseases or disorders

Various methods and compositions of treating 4-hydroxyphenylpyruvate dioxygenase-like (HPDL)-related diseases or disorders are presented herein. Also presented herein are methods of increasing CoQ10 biosynthesis, and methods of determining whether a subject will benefit from a CoQ10 or CoQ10 alternative treatment. Also presented herein are pharmaceutical compositions and dosage forms comprising 4-hydroxymandelic acid (4-HMA), and / or its metabolites. Further presented herein are compounds that inhibit 4-hydroxyphenylpyruvate dioxygenase-like (HPDL). Further presented herein are methods of identifying and / or assessing modulators of HPDL. Yet further presented herein are example methods and systems for isotopic labelling in cells by metabolizing cells in the presence of gaseous isotopic tracer.
Owner:NEW YORK UNIV

Immunosuppression therapy to mitigate immune responses against soluble alkaline phosphatase

The present disclosure features methods for treating neutralizing antibodies that reduce the efficacy of soluble alkaline phosphatase therapy (e.g., asfoenzyme alpha), which is an enzyme replacement therapy, such as for the treatment of bone mineralization disorders, e.g., hypophosphoesterase (HPP). The methods include diagnosing the subject for the presence of a neutralizing antibody that affects the efficacy of the treatment, administering a treatment suitable for reducing the deleterious effects of the neutralizing antibody, and continuing an alkaline phosphatase treatment.
Owner:ALEXION PHARMACEUTICALS INC

Application of flavin monooxygenase 3 inhibitor in preparation of medicine for preventing and / or treating acute pancreatitis

The invention provides application of a flavin monooxygenase 3 inhibitor in preparation of a medicine for preventing and / or treating acute pancreatitis, and belongs to the technical field of medicines. The flavin monooxygenase 3 inhibitor is methimazole or a pharmaceutically acceptable salt, a prodrug or a derivative of methimazole. Experimental results show that after the methimazole is orally taken, the nidus area of animal pancreatitis is obviously reduced, the pathological score is obviously improved, the in-vivo inflammation level is obviously inhibited, and the blood amylase and lipase levels are obviously reduced; the levels of pancreatitis factors and chemotactic factors are reduced, and the oxidative stress index is reduced. In addition, by combining methimazole with the traditional Chinese medicine monomer for inhibiting the trimethylamine oxide level, the curative effect is better. Compared with the prior art, the application has the advantages that the core regulation effect of the trimethylamine oxide in the pathological process of the acute pancreatitis is disclosed for the first time, the limitation of the traditional anti-inflammatory or enzyme replacement therapy is broken through, and the acute pancreatitis is treated by inhibiting the trimethylamine oxide level by inhibiting the flavin monooxygenase 3.
Owner:FIRST AFFILIATED HOSPITAL OF DALIAN MEDICAL UNIV

Information provision method for determining initiation of renal replacement therapy, and end-stage renal disease diagnostic composition for determining same

The present invention relates to an information provision method for determining the initiation of renal replacement therapy, the method comprising a step for checking the neutrophil-to-lymphocyte ratio in a sample isolated from an individual. The present invention enables the initiation of renal replacement therapy at an optimal time and the prediction of uremic symptoms, thereby enabling a prognosis of a patient to be greatly improved.
Owner:GYEONGSANG NAT UNIV HOSPITAL

Pharmaceutical compositions containing heparan N-sulfatase with improved stability

The present invention relates to a pharmaceutical composition for CNS delivery of high-concentration heparan N-sulfatase (HNS) with improved stability, and a pharmaceutical dosage form containing the same. The pharmaceutical composition and pharmaceutical dosage form containing the same according to the present invention have excellent dosage form stability, such as reduced turbidity and significantly improved purity, and are therefore useful in enzyme replacement therapy (ERT) for the treatment of mucopolysaccharidosis type III.
Owner:GC BIOPHARMA CORP

Comprehensive climacteric woman health management system

The invention discloses a comprehensive climacteric woman health management system, and belongs to the technical field of health management. A comprehensive climacteric woman health management system comprises an information acquisition module, a health prediction module, a health guidance module and an information storage module. The problems that in the prior art, only the current health state of the climacteric woman can be evaluated, and hidden health problems and trends are difficult to find are solved, the information of the climacteric woman is stored by establishing the distributed storage area, the safety of long-term storage of the information of the climacteric woman is guaranteed, the resource utilization rate is optimized, and the user experience is improved. Potential risks of osteoporosis, hypertension, coronary heart disease and other diseases can be recognized, timely intervention is performed to delay or avoid disease development, the overall health level is improved, early psychological intervention is facilitated, common mood troubles in climacteric are relieved, the estrogen decline degree can be determined, a hormone replacement therapy scheme can be made in an assisted mode, and the development period of the disease is shortened. And the living quality of climacteric women is improved.
Owner:无锡市锡山人民医院

Ultrasonic sensitization nanometer material based on MOFs and preparation method and application of ultrasonic sensitization nanometer material

The invention discloses an ultrasonic sensitized nano material based on MOFs (Metal-Organic Frameworks) as well as a preparation method and application thereof, and belongs to the technical field of biological materials. Comprising drug-loaded MOFs; the MOFs is selected from the group consisting of UiO-66-NH2; the UiO-66-NH2 is a particle formed by connecting an amino functional group to UiO-66; an m6A-mRNA (Messenger Ribonucleic Acid) demethylase inhibitor compound is loaded in the medicine carrying MOFs; the m6A-mRNA demethylase inhibitor compound is formed by coordination of a Rhein molecule and a bivalent copper ion; the outer surface of the drug-loaded MOFs is combined with an anti-CD19 antibody; and the outer surface of the drug-loaded MOFs is also modified with mPEG-PO3 (mPEG (Polyethylene Glycol)-PO3). As a replacement therapy of BCL, the MOFs-based ultrasonic sensitized nanomaterial can specifically gather in BCL tissues to play a therapeutic role after being functionalized by mPEG-PO3 and an anti-CD19 antibody.
Owner:JILIN UNIVERSITY

Compositions for treating Sanfilippo syndrome type A (MPS IIIA) comprising heparan N-sulfatase (HNS)

PendingCN122121891AOrganic active ingredientsNervous disorderSanfilippo syndrome type aPharmaceutical drug
The present invention relates to a pharmaceutical composition for preventing or treating Sanfilippo syndrome type A (MPS IIIA) comprising heparan N-sulfatase (HNS), and more particularly, to an optimal dose and period of administration of heparan N-sulfatase, which can effectively reduce the accumulation of heparan sulfate (HS) while improving the cognition of patients. According to the present invention, it can be used as enzyme replacement therapy (ERT) for treating Sanfilippo syndrome type A.
Owner:KOREA GREEN CROSS CORP

Human PAH expression cassette for treatment of PKU by liver-directed gene replacement therapy

Provided herein are expression cassettes for expressing a transgene in a liver cell, wherein the transgene encodes a PAH polypeptide. Also provided are methods to treat phenylketonuria (PKU) and / or to reduce levels of phenylalanine in an individual in need thereof. Further provided herein are vectors (e.g., rAAV vectors), viral particles, pharmaceutical compositions and kits for expressing a PAH polypeptide in an individual in need thereof.
Owner:GENZYME CORP

Therapeutic adeno-associated virus for treating pompe disease with long term cessation of gaa enzyme replacement therapy

PendingEP4482516A4Metabolism disorderPeptide/protein ingredientsVirusGlycogen storage disease type II
Disclosed herein are methods for the treatment of Pompe Disease comprising administering a recombinant AAV (rAAV) vector comprising a rAVV genome comprising a heterologous nucleic acid encoding an acid alpha-glucosidase (GAA) polypeptide operatively linked to a liver-specific promoter, wherein the subject is withdrawn or not administered enzyme replacement therapy (ERT).
Owner:ASKBIO INC +1

Marker for acid sphingomyelinase disorders and uses thereof

ActiveUS20240398907A1Peptide/protein ingredientsHydrolasesBiochemistryAcid sphingomyelinase
The present disclosure provides methods of screening, diagnosing, monitoring and / or treating acid sphingomyelinase (ASM) disorders such as Niemann-Pick disease. In particular, the methods encompass techniques for improved diagnosis and / or treatment of an ASM disorder, for example using enzyme replacement therapy.
Owner:GENZYME CORP

Natural Combination Hormone Replacement Formulations and Therapies

Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
Owner:THERAPEUTICSMD INC